Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 11/20 | 0.63 |
| ▸ | PDE4A | P27815 | 11/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.63 |
| ▸ | MMP2 | P08253 | 10/20 | 0.63 |
| ▸ | MMP1 | P03956 | 8/20 | 0.63 |
| ▸ | BMP1 | P13497 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.44 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.44 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.44 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823452 | 0.87 | PDE4A (0.62) | MMP3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7303121 | 0.85 | MMP2 (0.60) | MMP3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6819965 | 0.77 | PDE4A (1.00) | MMP3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31490743 | 0.77 | MMP1 (0.52) | MMP3MMP2MMP1MMP9 | |
| SCHEMBL6823664 | 0.76 | MMP3 (0.62) | MMP3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7308706 | 0.75 | MMP1 (0.46) | MMP3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7303711 | 0.74 | MMP2 (0.51) | MMP3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7441379 | 0.74 | MMP1 (0.46) | MMP3MMP2MMP1MMP9 | |
| SCHEMBL7309609 | 0.73 | MMP3 (0.53) | MMP3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10419211 | 0.72 | PPARA (0.47) | MMP3PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | claimed |